中国肿瘤外科杂志2025，Vol.17Issue(3)：248-256,9.DOI:10.3969/j.issn.1674-4136.2025.03.007
阿帕替尼联合紫杉醇/顺铂治疗非小细胞肺癌的疗效与安全性的Meta分析
Efficacy and safety of apatinib combined with paclitaxel/cisplatin in the treatment of non-small cell lung cancer:A Meta-analysis
摘要
Abstract
Objective To systematically analyze the efficacy and safety of apatinib combined with paclitaxel/cisplatin in the treatment of non-small cell lung cancer(NSCLC).Methods Chinese and foreign databases such as CNKI,Wanfang,VIP,PubMed and Cochrane Library were searched.Randomized controlled trials of apatinib in combination with paclitaxel/cisplatin in NSCLC were included.Patients in the control group received paclitaxel monotherapy or in combination with cisplatin chemotherapy regimen,while patients in the study group received apatinib tablets on the basis of treatment control group treatment.Data extracted including:primary outcomes(efficacy,adverse effects)and secondary outcomes(quality of life,tumor markers,etc.).Results A total of 34 studies were included in the Meta-analysis.For NSCLC,the objective remission rate and disease control rate were significantly higher in the study group than in the control group,with(RR=1.34,95%CI:1.22-1.47,P＜0.05)and(RR=1.11,95%CI:1.04-1.19,P＜0.05),respectively.In terms of quality of life,the KPS scores and SF-36 scores in the study group were higher than those of paclitaxel monotherapy or paclitaxel+cisplatin,respectively,with(WMD=5.32,95%CI:4.57-6.08,P＜0.05)and(WMD=11.45,95%CI:10.29-12.61,P＜0.05).In terms of the incidence of adverse effects(thrombocytopenia,leukopenia,erythrocytopenia,gastrointestinal reactions,hand-foot syndrome,etc.),there was no significant difference between the study group and the control group(RR=0.87,95%CI:0.74-1.02,P=0.086).In addition,in terms of tumor markers,the levels of CEA,Cyfra21-1,VEGF and MMP-9 in the study group were lower than those in the control group,respectively,with(WMD=-5.40,95%CI:-6.29 to-4.51,P＜0.05),(WMD=-1.82,95%CI:-2.64 to-1.01,P＜0.05),(WMD=-147.47,95%CI:-191.98 to-102.96,P＜0.05),and(WMD=-354.19,95%CI:-470.14 to-238.24,P＜0.05).Conclusions The better clinical efficacy of apatinib when combined with paclitaxel/cisplatin,in addition to the superimposed anti-tumor effect,and it may be related to the enhancement of the body's sensitivity to chemotherapeutic agents by apatinib,and the reversal of chemotherapeutic resistance to improve the efficacy of the treatment.关键词
阿帕替尼/紫杉醇/顺铂/非小细胞肺癌/疗效/安全性Key words
Apatinib/Paclitaxel/Cisplatin/Non-small cell lung cancer/Efficacy/Safety引用本文复制引用
李一帆,江洁美,黄灿..阿帕替尼联合紫杉醇/顺铂治疗非小细胞肺癌的疗效与安全性的Meta分析[J].中国肿瘤外科杂志,2025,17(3):248-256,9.基金项目
安徽省卫生健康科研项目(AHWJ2023BAa10001) （AHWJ2023BAa10001）
